- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.11. | NewcelX appoints ALS specialist to scientific advisory board | 1 | Investing.com | ||
| 17.11. | NewcelX Ltd.: NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute | 93 | PR Newswire | ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
| 17.11. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11. | Neurology expert Prof. Ben-Hur joins NewcelX scientific board | 2 | Investing.com | ||
| 04.11. | NewcelX Ltd.: NewcelX CEO Issues Letter to Shareholders | 134 | PR Newswire | ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies... ► Artikel lesen | |
| 03.11. | NewcelX Ltd.: NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. | 201 | PR Newswire | ZURICH, Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based... ► Artikel lesen | |
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 03.11. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.10. | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger / Combined Company Re-Named NewcelX Ltd. | 506 | PR Newswire | Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"
ZURICH and NESS ZIONA... ► Artikel lesen | |
| 30.10. | NSE/A - NLS Pharmaceutics Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 30.10. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.10. | NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger | 636 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system... ► Artikel lesen | |
| 29.10. | NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem | 249 | PR Newswire | ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 29.10. | NLS Pharmaceutics to execute 1-for-10 reverse share split | 1 | Seeking Alpha | ||
| 29.10. | NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares | 267 | PR Newswire | ZURICH and NESS ZIONA, Israel, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today... ► Artikel lesen | |
| 27.10. | NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies | 545 | PR Newswire | The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq:... ► Artikel lesen | |
| 23.10. | NLS Pharmaceutics and Kadimastem merger to close Oct. 30 after Nasdaq approval | 2 | Investing.com | ||
| 23.10. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.10. | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 | 1.914 | PR Newswire | ZURICH, Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system... ► Artikel lesen | |
| 10.10. | Fusion mit Kadimastem: NLS Pharmaceutics reicht Finanzberichte ein | 1 | Investing.com Deutsch | ||
| 10.10. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,985 | -1,11 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,36 | -0,47 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,370 | +0,99 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| JANUX THERAPEUTICS | 33,970 | 0,00 % | Janux-Aktie bricht nach Studiendaten nachbörslich um 26 % ein | ||
| RECURSION PHARMACEUTICALS | 4,365 | 0,00 % | Recursion Pharmaceuticals registriert Aktienpaket für Wiederverkauf durch Tempus AI | ||
| ARCUTIS BIOTHERAPEUTICS | 30,365 | 0,00 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| NUVALENT | 106,41 | -2,67 % | Nuvalent closes $500 million public offering of common stock | ||
| OLEMA PHARMACEUTICALS | 27,970 | -1,41 % | From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? | LONDON (dpa-AFX) - The biotech sector continues to deliver headline-grabbing moves, with stocks surging to fresh highs and companies advancing pivotal trials, regulatory filings, and strategic... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 184,53 | -5,83 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| MINERALYS THERAPEUTICS | 40,690 | -5,61 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 39,790 | -1,14 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| SPRUCE BIOSCIENCES | 83,95 | 0,00 % | Spruce Biosciences - SPRB: Citizens stuft auf "Market Outperform" hoch! | Einlizenzierung von TA-ERT! Bis zu 170 Mio. Umsatz p.a.! Spruce Biosciences (SPRB) will Zulassungsantrag im I. Quartal 2026 einreichen. Spruce Biosciences (SPRB) - ISIN US85209E2081 Rückblick: Knaller-Setup... ► Artikel lesen | |
| ARCELLX | 70,30 | -4,03 % | CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting | ||
| BIONTECH | 84,05 | -5,51 % | CureVac: Cash bis 2028 - BioNTechs Offerte läuft noch bis zum 3.12. | CureVac hat einen Tag vor der außerordentlichen Hauptversammlung im Zusammenhang mit der laufenden Übernahme durch BioNTech Zahlen vorgelegt. Das Tübinger Biotech-Unternehmen meldet einen Bestand an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,910 | 0,00 % | Nurix to host webcast on bexobrutideg clinical data next week |
Das Unternehmen NEWCELX LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,220 (-5,50 %) liegt der Kurs bei 3,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.